Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This compounded injectable formulation has not been reviewed or approved by the U.S
(1988) characterized IGFBP binding determinants in the IGF-1 molecule, providing the structural basis for the R3 substitution that became the foundation of the LR3 design (PMID 3356790)
Sources Jones DP, Sies H
Egrifta (tesamorelin for injection) Prescribing Information
These peptides are used to support healing of soft tissue, calm inflammation, and help the body bounce back from the microdamage of hard training or a nagging injury
The COA links directly from this product page to the Janoshik verification platform for independent confirmation of compound identity, purity and copper content
US$ 21.12
US$ 29.43
US$ 24.59
US$ 25.40
US$ 23.08
US$ 22.90
US$ 26.17
US$ 20.12
